Publication Brief

Cancer therapy-associated neurotoxicities can exert debilitating effects on patients and negatively impact the course of cancer treatment. There is a critical need for accurate biomarker tests that could predict the onset as well as assess the severity of neurotoxicities. In addition, such tests could potentially provide realtime feedback to clinicians during treatment to proactively adjust or fine-tune cancer therapy regimen and for supportive care for patients who experience acute or long-term toxicities. Recent data from a number of clinical studies have shown that blood-based Simoa® biomarker assays (NfL, etc.) are promising as predictive and quantitative biomarkers for cancer therapy associated neurotoxicities. Download our publication brief to learn more.